Erasca, Inc. (ERAS)
Erasca, Inc. (ERAS) is a healthcare company (biotechnology) based in the United States. The share price is $14.53, down 3.84% on the day, which values the company at $5.1B. Price as of 17 Nov 2026, 17:13 UTC, from Yahoo Finance.
Key facts
- Share price
- $14.53−3.84% today
- Market value
- $5.1B
- 200-week average
- $5.18180% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Erasca, Inc. in more detail
ERAS trades at -19.4× next year's expected earnings. It sits 180% above its 200-week average of $5.18.
In its favour: More cash than debt. Worth checking: Weak Piotroski score; Share count keeps rising.
Health Care companies of similar size
- GRAILGRAL
- LifeStance Health GroupLFST
- BillionToOneBLLN
- Hims & Hers HealthHIMS
- PTC TherapeuticsPTCT
- HaemoneticsHAE
- Concentra Group Holdings ParentCON
- Merit Medical SystemsMMSI
- Edgewise TherapeuticsEWTX
- LivaNovaLIVN
- Ionis PharmaceuticalsIONS
- Dianthus TherapeuticsDNTH
Side by side:ERAS vs CON (Erasca, Inc. vs Concentra Group Holdings Parent)ERAS vs HAE (Erasca, Inc. vs Haemonetics)ERAS vs PTCT (Erasca, Inc. vs PTC Therapeutics)ERAS vs HIMS (Erasca, Inc. vs Hims & Hers Health)ERAS vs MMSI (Erasca, Inc. vs Merit Medical Systems)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Erasca, Inc. (ERAS): questions and answers
What is Erasca, Inc.'s market cap?
Erasca, Inc. is valued at $5.1B at a share price of $14.53.
Is ERAS above its 200-week moving average?
Yes. ERAS is 180.3% above its 200-week average of $5.18. Long-term investors watch that line because strong companies rarely trade below it for long.
Does ERAS pay a dividend?
Erasca, Inc. does not currently pay a regular dividend.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Erasca, Inc. (ERAS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ERAS
Underlying data: Yahoo Finance; company filings with the SEC.